In this issue:
Deferasirox for 3 years improves myocardial T2*
Imatinib discontinuation in CML
Imatinib and OCT-1 activity in chronic phase CML
FCGR-3A genotype predicts
OS in rituximab-treated follicular lymphoma 5-year outcomes after response to rituximab in ITP Borte
Please login below to download this issue (PDF)